| Trial ID: | L2060 |
| Source ID: | NCT01072331
|
| Associated Drug: |
Mp-513
|
| Title: |
Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01072331/results
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: MP-513|DRUG: MP-513|DRUG: Placebo of MP-513
|
| Outcome Measures: |
Primary: Change From Baseline in 2-h Postprandial Glucose (Breakfast, Lunch and Dinner), 4 weeks|Change From Baseline in Plasma Glucose Area Under the Curve (AUC) 0 to 2h (Breakfast, Lunch and Dinner), 4 weeks | Secondary: Change From Baseline in 24-h Mean Glucose, 4 weeks|Change From Baseline in Fasting Plasma Glucose, 4 weeks
|
| Sponsor/Collaborators: |
Sponsor: Mitsubishi Tanabe Pharma Corporation
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
99
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2010-02
|
| Completion Date: |
2010-08
|
| Results First Posted: |
2012-12-19
|
| Last Update Posted: |
2013-04-09
|
| Locations: |
Suita, Osaka, Japan
|
| URL: |
https://clinicaltrials.gov/show/NCT01072331
|
